Latest California Healthline Stories
Consumer Group Questions Role of Drug Costs In California Premium Hikes
Consumers Union says Anthem Inc. and Blue Shield of California may be exploiting furor over prescription drug prices. State regulators are looking into the issue.
Should Health Care Providers Receive Special Protection From Secret Taping?
Gov. Jerry Brown must decide whether to sign a bill sponsored by Planned Parenthood that would criminalize distribution of a surreptitiously recorded conversation with a medical professional.
Behind The EpiPen Monopoly: Lobbying, Flailing Competition And Tragedy
The death of a Sacramento girl paved the way for a state law that strengthened the demand for EpiPens in California.
EpiPen Controversy Fuels Concerns Over Generic Drug Approval Backlog
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.
Attending To The ‘Human Element’ Is Key To Keeping Patients Healthy
Research to be published in full this fall details how medicine’s “implicit bias” — whether real or perceived — undermines the doctor-patient relationship and the well-being of racial and ethnic minorities as well as lower-income patients.
Gaps In Care Persist During Transition From Hospital To Home
A partnership between San Diego County and four health systems seeks to bridge the longstanding gap between hospitals and social services.
What Happens When A Living Kidney Donor Needs A Transplant?
A new study examines how well efforts are working that prioritize the needs of these patients if they end up needing a kidney transplant of their own.
High-Profile Initiative To Pool Medical Records Lags In California
‘Progress has been slower than we hoped,’ says one official at Cal INDEX, backed by $80 million from two large insurers.
Mylan’s Generic EpiPen — A Price Break Or Marketing Maneuver?
As news that Mylan will make available a generic version of its own brand-name product, KHN answers key questions about how this development could affect consumers.
Patients, Fearing Pricey Follow-Ups, May Shy Away From Some Colon Cancer Tests
Most screening tests for colon cancer are covered by insurance but if they come back positive, they may require a diagnostic colonoscopy and that may not be covered completely by insurance.